UniSuper Management Pty Ltd Has $1.72 Million Stock Holdings in DaVita Inc. (NYSE:DVA)

UniSuper Management Pty Ltd raised its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 21.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,506 shares of the company's stock after purchasing an additional 2,063 shares during the period. UniSuper Management Pty Ltd's holdings in DaVita were worth $1,721,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Franklin Resources Inc. increased its stake in shares of DaVita by 134.6% in the 3rd quarter. Franklin Resources Inc. now owns 54,901 shares of the company's stock valued at $8,885,000 after purchasing an additional 31,502 shares during the last quarter. FMR LLC boosted its stake in DaVita by 659.9% in the third quarter. FMR LLC now owns 177,406 shares of the company's stock valued at $29,082,000 after buying an additional 154,061 shares in the last quarter. Atom Investors LP bought a new position in DaVita in the third quarter valued at about $4,094,000. Assenagon Asset Management S.A. raised its stake in DaVita by 201.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company's stock worth $11,159,000 after acquiring an additional 49,885 shares in the last quarter. Finally, Neo Ivy Capital Management bought a new position in shares of DaVita in the third quarter worth about $726,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on DVA. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. Cowen reaffirmed a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. StockNews.com downgraded DaVita from a "buy" rating to a "hold" rating in a report on Wednesday. Finally, Barclays upped their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $166.33.

Remove Ads

DaVita Trading Down 2.8 %

Shares of DaVita stock traded down $4.37 during trading on Friday, hitting $149.37. The company's stock had a trading volume of 1,009,511 shares, compared to its average volume of 811,855. The stock has a market cap of $11.95 billion, a price-to-earnings ratio of 13.91, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04. DaVita Inc. has a 52 week low of $125.64 and a 52 week high of $179.60. The stock has a 50-day moving average price of $155.75 and a two-hundred day moving average price of $157.28. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Equities research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.